People · Operator
Named in public records as an officer, director or promoter · active 2008–2023 · Other Health Care, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TV2 HOLDING Co | — | Other Health Care | Series C | $173.7M | $228.6M | 2009 |
| Dermira, Inc. | — | Other Health Care | Series C | $113.0M | $22.9M | 2011 |
| Hyperion Therapeutics Inc | — | Pharmaceuticals | Series B | $67.9M | $271.7M | 2008 |
| Addex Therapeutics Ltd. | — | Biotechnology | Series A | $13.9M | $35.6M | 2021 |
| Aciex Therapeutics, Inc. | — | Biotechnology | Series A | $9.6M | $57.8M | 2011 |
Jake Nunn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jake Nunn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jake R. Nunn | 3 | 4 |
| Ryan Drant | 1 | 24 |
| David Kim | 1 | 17 |
| Wende Hutton | 1 | 16 |
| James Healy | 1 | 8 |
| Robert Thomas | 1 | 8 |
| EUGENE A. BAUER | 1 | 7 |
| James I. Healy | 1 | 7 |
| Rob Hopfner | 1 | 6 |
| DANIEL MOORE | 1 | 6 |
| Arun Ramamoorthy | 1 | 5 |
| JAMES SHAPIRO | 1 | 5 |
| Douglas Roeder | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Bijan Salehizadeh | 1 | 5 |
| Lota S Zoth | 1 | 4 |
| Dayton Misfeldt | 1 | 4 |
| Douglas A. Roeder | 1 | 4 |
| David E. Cohen | 1 | 4 |
| Donald Santel | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.